Hisky Medical proudly exhibited at ENDO 2026, the Endocrine Society’s premier annual meeting, held June 13–15 at McCormick Place in Chicago, USA. As the global flagship event for endocrinology and metabolic medicine, ENDO brought together leading specialists across thyroid, pituitary, adrenal, reproductive, bone and metabolic disorders to advance clinical practice and scientific discovery. At Booth #3932, Hisky featured dedicated liver scan demo promotions that successfully attracted targeted clinical visitors, and the team registered over 170 qualified leads throughout the congress, with a high share of practicing endocrinologists reflecting the strong clinical relevance and quality of engagement.

Aligned with ENDO’s focus on metabolic dysfunction, obesity-related comorbidities and the systemic impact of hormonal disorders, Hisky’s team shared clinical evidence on the close associations between MASLD/MASH, hypogonadism, visceral adiposity and cardiometabolic risk, illustrating how point-of-care transient elastography can empower endocrinologists to identify progressive liver disease earlier in daily practice.

Notably, Hisky held multiple rounds of in-depth strategic discussions with Madrigal Pharmaceuticals, a key player in MASH therapeutics, to lay the foundation for deepened U.S. market collaboration and potential joint promotion activities. Insights from the congress also reinforced growing clinical demand for muscle mass assessment tools and the need for further medical education on transient elastography within the endocrinology community, shaping Hisky’s upcoming product and market strategy.